Logo image of HSCS

HEARTSCIENCES INC (HSCS) Stock Fundamental Analysis

NASDAQ:HSCS - Nasdaq - US42254E3027 - Common Stock - Currency: USD

3.5734  -0.03 (-0.74%)

After market: 3.51 -0.06 (-1.77%)

Fundamental Rating

3

HSCS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. While HSCS seems to be doing ok healthwise, there are quite some concerns on its profitability. HSCS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HSCS has reported negative net income.
In the past year HSCS has reported a negative cash flow from operations.
In the past 5 years HSCS always reported negative net income.
HSCS had a negative operating cash flow in each of the past 5 years.
HSCS Yearly Net Income VS EBIT VS OCF VS FCFHSCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

Looking at the Return On Assets, with a value of -115.80%, HSCS is doing worse than 85.64% of the companies in the same industry.
With a Return On Equity value of -369.69%, HSCS is not doing good in the industry: 86.17% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -115.8%
ROE -369.69%
ROIC N/A
ROA(3y)-164.63%
ROA(5y)-163.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HSCS Yearly ROA, ROE, ROICHSCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

With a decent Gross Margin value of 67.20%, HSCS is doing good in the industry, outperforming 73.94% of the companies in the same industry.
In the last couple of years the Gross Margin of HSCS has grown nicely.
The Profit Margin and Operating Margin are not available for HSCS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.91%
GM growth 5YN/A
HSCS Yearly Profit, Operating, Gross MarginsHSCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

5

2. Health

2.1 Basic Checks

HSCS does not have a ROIC to compare to the WACC, probably because it is not profitable.
HSCS has less shares outstanding than it did 1 year ago.
HSCS has a better debt/assets ratio than last year.
HSCS Yearly Shares OutstandingHSCS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
HSCS Yearly Total Debt VS Total AssetsHSCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

HSCS has an Altman-Z score of -21.21. This is a bad value and indicates that HSCS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of HSCS (-21.21) is worse than 90.43% of its industry peers.
There is no outstanding debt for HSCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -21.21
ROIC/WACCN/A
WACC8.41%
HSCS Yearly LT Debt VS Equity VS FCFHSCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M -2M 4M -4M 6M -6M

2.3 Liquidity

HSCS has a Current Ratio of 1.02. This is a normal value and indicates that HSCS is financially healthy and should not expect problems in meeting its short term obligations.
HSCS has a worse Current ratio (1.02) than 89.36% of its industry peers.
HSCS has a Quick Ratio of 1.02. This is a bad value and indicates that HSCS is not financially healthy enough and could expect problems in meeting its short term obligations.
HSCS has a Quick ratio of 0.83. This is amonst the worse of the industry: HSCS underperforms 84.57% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 0.83
HSCS Yearly Current Assets VS Current LiabilitesHSCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

5

3. Growth

3.1 Past

HSCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.40%, which is quite impressive.
The Revenue has grown by 257.69% in the past year. This is a very strong growth!
The Revenue for HSCS have been decreasing by -10.10% on average. This is quite bad
EPS 1Y (TTM)50.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.33%
Revenue 1Y (TTM)257.69%
Revenue growth 3Y-10.1%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 24.81% on average over the next years. This is a very strong growth
HSCS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 358.08% yearly.
EPS Next Y80.6%
EPS Next 2Y36.08%
EPS Next 3Y24.81%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y289.58%
Revenue Next 3Y358.08%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HSCS Yearly Revenue VS EstimatesHSCS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2026 2027 1M 2M 3M 4M 5M
HSCS Yearly EPS VS EstimatesHSCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HSCS. In the last year negative earnings were reported.
Also next year HSCS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HSCS Price Earnings VS Forward Price EarningsHSCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HSCS Per share dataHSCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20 -25

4.3 Compensation for Growth

HSCS's earnings are expected to grow with 24.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.08%
EPS Next 3Y24.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HSCS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HEARTSCIENCES INC

NASDAQ:HSCS (6/13/2025, 8:07:27 PM)

After market: 3.51 -0.06 (-1.77%)

3.5734

-0.03 (-0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-13 2025-03-13/amc
Earnings (Next)N/A N/A
Inst Owners1.16%
Inst Owner Change1267.52%
Ins Owners4.96%
Ins Owner Change0%
Market Cap3.86M
Analysts82.5
Price Target13.26 (271.08%)
Short Float %0.97%
Short Ratio0.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.05%
Min EPS beat(2)-6.31%
Max EPS beat(2)8.42%
EPS beat(4)1
Avg EPS beat(4)-107.45%
Min EPS beat(4)-426.89%
Max EPS beat(4)8.42%
EPS beat(8)3
Avg EPS beat(8)-53.65%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.35%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 207.49
P/FCF N/A
P/OCF N/A
P/B 2.16
P/tB 21.66
EV/EBITDA N/A
EPS(TTM)-26.29
EYN/A
EPS(NY)-7.54
Fwd EYN/A
FCF(TTM)-6.94
FCFYN/A
OCF(TTM)-6.81
OCFYN/A
SpS0.02
BVpS1.65
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -115.8%
ROE -369.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.2%
FCFM N/A
ROA(3y)-164.63%
ROA(5y)-163.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.91%
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 335.88%
Cap/Sales 709.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 0.83
Altman-Z -21.21
F-Score3
WACC8.41%
ROIC/WACCN/A
Cap/Depr(3y)174.76%
Cap/Depr(5y)108.85%
Cap/Sales(3y)346.26%
Cap/Sales(5y)211.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.33%
EPS Next Y80.6%
EPS Next 2Y36.08%
EPS Next 3Y24.81%
EPS Next 5YN/A
Revenue 1Y (TTM)257.69%
Revenue growth 3Y-10.1%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y289.58%
Revenue Next 3Y358.08%
Revenue Next 5YN/A
EBIT growth 1Y-3.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.72%
EBIT Next 3Y-6.59%
EBIT Next 5YN/A
FCF growth 1Y-46.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-44.17%
OCF growth 3YN/A
OCF growth 5YN/A